Future Directions in HER2-Positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.

Sara A. Hurvitz, MD: It continues to be a really exciting time in the HER2 [human epidermal growth factor receptor 2] world. A number of agents are under investigation, including novel antibody-drug conjugates, immune-based therapies, and CDK4/6 inhibitors. I think the outcomes are going to continue to improve for women, and hopefully, we’ll be curing more women and treating fewer with metastatic disease. However, in the short-term setting, I think we’re going to be seeing some changes based on the results from clinical trials that have completed enrollment, looking at whether we can move T-DXd [trastuzumab deruxtecan] into the second-line setting, and whether we will be adding tucatinib to T-DM1 [trastuzumab emtansine]. Studies are looking at the use of tucatinib in early stage disease, as well as T-DXd in early stage disease. So, I think the landscape and our guidelines regarding how to sequence and use these agents is going to rapidly change in the next 2 to 3 years. It’s a very exciting time.

Transcript Edited for Clarity

Related Videos
Nathalie McDowell Johnson, MD, FACS
William M. Sikov, MD
Lisa A. Carey MD, ScM, FASCO
Susan Domchek, MD, FASCO
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Jean Wright, MD
Steven Cai, MD, FACS
Hyman B. Muss, MD
Expert on breast cancer
Priyanka Sharma, MD
Related Content